Balanced news tone
News Sentiment
RZLT sentiment intelligence
Rezolute Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
52 relevant articles
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-3.3% over one week, +18.8% over four weeks, trend active, and near fair-value range.
Form 4 Rezolute Inc For: 7 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
77/100 classification
One-week reaction
-3.3%
Price reacting lower
Trend fit
Trend active
18.8% over four weeks
Fair value
21.7%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
33
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com Nigeria
Direct company coverage
Form 4 Rezolute Inc For: 7 July By Investing.com
The article reports on a Form 4 filing for Rezolute Inc., specifically for July 7th. Form 4s disclose transactions by company insiders, and this article provides a brief mention without detailing the specifics of the filing. It is primarily a placeholder announcement from Investi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 22:39
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
Rezolute (RZLT) CMO disposes 3,062 shares in mandated RSU tax sale
Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, reported a disposition of 3,062 common shares to cover tax withholding obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $4.99 per share, was a mandated "sell to cover" arrangeme
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Rezolute (RZLT) CFO logs RSU tax sell-to-cover, retains 411,400 shares
Rezolute, Inc.'s CFO, Daron Evans, reported a tax-related disposition of 3,062 common shares at $4.99 each. This "sell-to-cover" transaction was mandated by the company to satisfy tax withholding obligations related to Restricted Stock Unit vesting, not a discretionary trade. Fol
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 21:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Rezolute (RZLT) CEO logs automatic RSU tax-withholding share sale in Form 4
Rezolute, Inc. CEO Nevan C. Elam reported an automatic sale of 8,004 common shares for $4.99 per share to cover tax withholding obligations from vested Restricted Stock Units. This was a mandatory "sell to cover" transaction, not a discretionary market trade. Following this dispo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 21:11
- Source
- Stock Titan
Finviz
Direct company coverage
RZLT - Rezolute Inc Options
This article provides a detailed financial overview of Rezolute Inc (RZLT), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers insider ownership, institutional ownership, quarterly and yearly EPS and sales performanc
- Tone
- Negative 41/100
- Event
- Earnings
- Published
- 04 Jul 2026 14:10
- Source
- Finviz
TradingView
Direct company coverage
Price to sales forward of Rezolute, Inc. – NASDAQ:RZLT
This article provides financial information for Rezolute, Inc. (NASDAQ: RZLT), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades recorded. The content seems to be a placeholder or a very brief data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 19:42
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Rezolute, Inc. – NASDAQ:RZLT
This article provides a financial snapshot for Rezolute, Inc. (NASDAQ: RZLT), focusing on its forward price-to-earnings ratio. It indicates current market status as closed with no trades. The article is primarily a data page from TradingView, displaying basic company information
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 19:09
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Rezolute, Inc. – NASDAQ:RZLT
This article provides access to the "Price to book forward" metric for Rezolute, Inc. (NASDAQ: RZLT). It appears to be a financial data page from TradingView, offering an overview of the company's financial information.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 06:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Rezolute, Inc. – DUS:6HV1
This article provides the enterprise value to revenue forward for Rezolute, Inc. (DUS:6HV1) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily serves as a financial data point without further analysis or detail
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 05:09
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Rezolute, Inc. – DUS:6HV1
The article mentions the "Price to earnings forward" metric for Rezolute, Inc. (DUS:6HV1), listed on the Dusseldorf Stock Exchange. It indicates no current trading activity for the stock, as the market is closed and no trades have occurred. The content is presented as a financial
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 22:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Rezolute, Inc. – NASDAQ:RZLT
This article focuses on the "Enterprise value to revenue forward" metric for Rezolute, Inc. (NASDAQ: RZLT). It is a brief financial snippet provided by TradingView, indicating a key valuation ratio for the company's stock. The content itself provides very little information beyon
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 09:39
- Source
- TradingView
TradingView
Direct company coverage
Rezolute, Inc. Actuals & Estimates (NASDAQ:RZLT)
This article provides an in-depth financial overview of Rezolute, Inc. (NASDAQ: RZLT), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It includes information on market capitalization, earnings, revenue, and employee count,
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 25 Jun 2026 21:10
- Source
- TradingView
Moomoo
Direct company coverage
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14
This article provides a quick look at analyst ratings for Rezolute (RZLT.US), noting a forecast price range between $5 and $14. Further details on the specific ratings and what informs this forecast were not available in the provided content.
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 25 Jun 2026 03:09
- Source
- Moomoo
Streetwise Reports
Direct company coverage
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth
Rezolute Inc. is making significant progress with its late-stage drug Ersodetug, targeting rare forms of hypoglycemia caused by hyperinsulinism. Recent data presented at ENDO 2026 and positive analyst ratings underscore the drug's potential in congenital and tumor-related hyperin
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 20 Jun 2026 15:08
- Source
- Streetwise Reports
Investing.com
Direct company coverage
Guggenheim raises Rezolute stock price target on trial outlook
Guggenheim has increased its price target for Rezolute Inc. (NASDAQ:RZLT) to $11 from $6, maintaining a Buy rating. This adjustment is based on the strong likelihood of positive results from the upLIFT registrational study in the latter half of 2026, with an interim update de-ris
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 20 Jun 2026 06:40
- Source
- Investing.com
Streetwise Reports
Direct company coverage
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data
Rezolute Inc. (RZLT:NASDAQ) presented encouraging data for its hypoglycemia treatment, ersodetug, at ENDO 2026, gaining attention from analysts who predict significant gains and a "Buy" rating. The company focuses on refractory hypoglycemia caused by hyperinsulinism and expects P
- Tone
- Positive 71/100
- Event
- Guidance
- Published
- 19 Jun 2026 15:39
- Source
- Streetwise Reports
TradingKey
Direct company coverage
Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Rezolute Inc (RZLT), detailing its current price momentum score, support and resistance levels. It also presents a summary of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, indicating a 'Buy' signal based on
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 19 Jun 2026 05:10
- Source
- TradingKey
TradingKey
Direct company coverage
Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Rezolute Inc (RZLT)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also presents current stock performance details for
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 21:40
- Source
- TradingKey
TradingKey
Direct company coverage
Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Rezolute Inc (RZLT). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article primarily displays general compa
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 20:39
- Source
- TradingKey
The Manila Times
Direct company coverage
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Rezolute, Inc. presented data at the Annual Meeting of the Endocrine Society on natural history outcomes in congenital hyperinsulinism (HI) and its ersodetug clinical program. Presentations included analyses of adverse outcomes in congenital HI, favorable results from an Expanded
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 17 Jun 2026 11:39
- Source
- The Manila Times
Stock Titan
Direct company coverage
Rezolute data: 75% of tumor HI patients came off IV dextrose at ENDO
Rezolute (Nasdaq: RZLT) announced that 75% of tumor hyperinsulinism (HI) patients in its Expanded Access Program (EAP) were able to discontinue IV dextrose/TPN support, as presented at the annual ENDO meeting. The company highlighted four presentations covering congenital and tum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 11:03
- Source
- Stock Titan
TradingKey
Direct company coverage
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Rezolute Inc's (RZLT) earnings forecast score is 8.20, ranking 153 out of 388 in its industry. Analysts have set an average price target of $17.00 for RZLT, with a strong "Buy" consensus rating based on 10 analysts. The previous quarter's EPS was -$0.22 against an expectation of
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 17 Jun 2026 10:39
- Source
- TradingKey
The Globe and Mail
Direct company coverage
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD)
Three analysts from H.C. Wainwright have issued bullish sentiments on healthcare companies Brainsway (BWAY), Rezolute (RZLT), and Invivyd (IVVD). Ram Selvaraju reiterated a Buy rating for Brainsway with a $17.00 price target, Douglas Tsao assigned a Buy rating for Rezolute with a
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 16 Jun 2026 10:33
- Source
- The Globe and Mail
GuruFocus
Direct company coverage
RZLT Maintained by Guggenheim -- Price Target Raised to $11.00
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Rezolute (RZLT) and significantly raised the price target to $11.00 from $6.00, representing an 83.33% increase. The company, a clinical-stage biopharmaceutical firm, is currently trading at $4.34, suggestin
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 15 Jun 2026 16:40
- Source
- GuruFocus
Simply Wall Street
Direct company coverage
Exploring 3 High Growth Tech Stocks in US Market
This article identifies three high-growth tech stocks in the US market: Rezolute (RZLT), SELLAS Life Sciences Group (SLS), and Larimar Therapeutics (LRMR). It provides an overview of each company, their current operations, and highlights their growth potential, innovative treatme
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 15 Jun 2026 11:40
- Source
- Simply Wall Street
Investing.com Canada
Direct company coverage
Guggenheim raises Rezolute stock price target on trial outlook By Investing.com
Guggenheim has increased its price target for Rezolute Inc. (NASDAQ: RZLT) from $6 to $11, maintaining a Buy rating, citing confidence in a positive outcome from the upLIFT registrational study in the latter half of 2026. The firm projects approximately $850 million in peak sales
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 15 Jun 2026 11:40
- Source
- Investing.com Canada
Market source
Direct company coverage
Positive Signs As Multiple Insiders Buy Rezolute Stock
Multiple insider purchases of Rezolute, Inc. (NASDAQ:RZLT) stock have been observed, signaling a positive outlook from company executives. Although individual purchases may not be significant, the collective buying suggests insiders view the stock favorably, particularly after a
- Tone
- Positive 72/100
- Event
- Guidance
- Published
- 10 Jun 2026 11:40
- Source
- Market source
GlobeNewswire
Direct company coverage
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 11:30
- Source
- GlobeNewswire
MT Newswires
Direct company coverage
Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 03 Jun 2026 11:00
- Source
- MT Newswires